News
Sarepta Therapeutics Inc. (NASDAQ:SRPT) is a commercial-stage biopharmaceutical company that discovers and develops ...
Scientists from the Centenary Institute and the University of Sydney have made a landmark discovery that could lead to safer and more effective gene therapies for a range of serious genetic disorders ...
From sarcopenia to ALS, researchers are exploring creatine’s broader clinical potential — but more trials are needed to confirm its value.
Scientists from the Centenary Institute and the University of Sydney have made a landmark discovery that could lead to safer ...
Capricor Therapeutics's dip caused by the CRL is a buying opportunity considering the readout of HOPE-3 within 2-3 months.
The applications of AI virtual human technology are rapidly expanding, demonstrating its value in social good and ...
Dyne Therapeutics, Inc. (NASDAQ: DYN) is one of the 13 Best Healthcare Stocks to Buy Under $10 . In a report released on July ...
The company said it was optimistic that the issues identified by the Food and Drug Administration could be resolved with new data.
Capricor Therapeutics Inc. said it has received a complete response letter from the U.S. FDA on the BLA for deramiocel to treat cardiomyopathy in Duchenne muscular dystrophy patients. The BLA has a ...
Capricor Therapeutics is expected to release data from the phase 3 HOPE-3 trial in Q3'25, thus presenting a potential path ...
The U.S. Food and Drug Administration has declined to approve Capricor Therapeutics' cell therapy for a heart condition, the ...
The company said it was “surprised” by the decision, which followed the ouster of cell and gene therapy officials from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results